白蛋白输注治疗方案对蛛网膜下腔出血患者迟发性脑缺血及相关结局的影响
该研究在哥伦比亚Cali一家三级大学医院ICU开展准实验研究(历史对照),纳入189例成人SAH患者,2011–2014年治疗者为对照组,2014–2018年治疗者为干预组。干预为2014年实施的机构管理方案:初始心脏评估、允许负液体平衡、ICU前5天以持续白蛋白输注为主要液体治疗,目标达到并维持等容量和血流动力学稳定。结果显示方案与DCI发生率降低(多变量子分布风险模型HR 0.52,95%CI 0.33–0.83)和低钠血症减少(RR 0.55,95%CI 0.37–0.80)相关,未伴院内或长期死亡率升高,也未增加肺水肿、再出血、脑积水、高钠血症、肺炎等不良结局。干预组每日及累计输液量低于历史对照组(p<0.0001)。作者认为该方案可能对SAH患者有益。
要点
- 对ICU成人SAH患者,ICU前5天以持续白蛋白输注为主要液体的管理方案与DCI发生率降低相关(多变量子分布风险模型HR 0.52,95%CI 0.33–0.83)。
- 该方案与低钠血症发生率降低相关(RR 0.55,95%CI 0.37–0.80)。
- 方案未伴院内或长期死亡率升高,也未增加肺水肿、再出血、脑积水、高钠血症、肺炎等不良结局。
- 干预组每日及累计输液量均低于历史对照组(p<0.0001)。
- 方案组成包括初始心脏评估、允许负液体平衡、持续白蛋白输注,目标为达到并维持等容量与血流动力学稳定。
适用人群与场景
- 哥伦比亚Cali一家三级大学医院ICU收治的成人蛛网膜下腔出血(SAH)患者;对照组为2011–2014年治疗者,干预组为2014–2018年治疗者。
处置流程与药物剂量
- 2014年起本院实施的机构管理方案:基于初始心脏评估、允许负液体平衡、ICU前5天以持续白蛋白输注作为主要液体治疗。
- 方案目标为达到并维持等容量和血流动力学稳定,以减少低血容量或血流动力学不稳定时段,预防ICU内缺血事件和并发症。
研究设计与关键结果
- 研究类型为准实验研究(历史对照),基于电子病历,纳入189例成人SAH患者,来自哥伦比亚Cali一家三级大学医院ICU。
- 干预组(2014–2018年治疗)与对照组(2011–2014年治疗)比较,管理方案与DCI发生率降低相关(多变量子分布风险模型HR 0.52,95%CI 0.33–0.83)。
- 管理方案与低钠血症发生率降低相关(RR 0.55,95%CI 0.37–0.80)。
- 管理方案未伴院内或长期死亡率升高,也未增加肺水肿、再出血、脑积水、高钠血症、肺炎等不良结局的发生。
- 干预组每日及累计输液量低于历史对照组(p<0.0001)。
证据类型、等级与局限
- 证据类型:准实验研究(历史对照),采用多变量分析和敏感性分析控制混杂并考虑竞争风险。
- 研究经机构伦理审查委员会批准后开始。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于血流动力学导向的液体治疗联合ICU前5天持续白蛋白输注作为主要液体的管理方案,可能对SAH患者有益,因其与DCI和低钠血症发生率降低相关。
- 作者提出可能机制包括改善血流动力学稳定性以达到等容量并降低缺血风险等。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: An institutional management protocol for patients with subarachnoid hemorrhage (SAH) based on initial cardiac assessment, permissiveness of negative fluid balances, and use of a continuous albumin infusion as the main fluid therapy for the first 5 days of the intensive care unit (ICU) stay was implemented at our hospital in 2014. It aimed at achieving and maintaining euvolemia and hemodynamic stability to prevent ischemic events and complications in the ICU by reducing periods of hypovolemia or hemodynamic instability. This study aimed at assessing the effect of the implemented management protocol on the incidence of delayed cerebral ischemia (DCI), mortality, and other relevant outcomes in patients with SAH during ICU stay.
METHODS: We conducted a quasi-experimental study with historical controls based on electronic medical records of adults with SAH admitted to the ICU at a tertiary care university hospital in Cali, Colombia. The patients treated between 2011 and 2014 were the control group, and those treated between 2014 and 2018 were the intervention group. We collected baseline clinical characteristics, cointerventions, occurrence of DCI, vital status after 6 months, neurological status after 6 months, hydroelectrolytic imbalances, and other SAH complication. Multivariable and sensitivity analyses that controlled for confounding and considered the presence of competing risks were used to adequately estimate the effects of the management protocol. The study was approved by our institutional ethics review board before study start.
RESULTS: One hundred eighty-nine patients were included for analysis. The management protocol was associated with a reduced incidence of DCI (hazard ratio 0.52 [95% confidence interval 0.33-0.83] from multivariable subdistribution hazards model) and hyponatremia (relative risk 0.55 [95% confidence interval 0.37-0.80]). The management protocol was not associated with higher hospital or long-term mortality, nor with a higher occurrence of other unfavorable outcomes (pulmonary edema, rebleeding, hydrocephalus, hypernatremia, pneumonia). The intervention group also had lower daily and cumulative administered fluids compared with historic controls (p < 0.0001).
CONCLUSIONS: A management protocol based on hemodynamically oriented fluid therapy in combination with a continuous albumin infusion as the main fluid during the first 5 days of the ICU stay appears beneficial for patients with SAH because it was associated with reduced incidence of DCI and hyponatremia. Proposed mechanisms include improved hemodynamic stability that allows euvolemia and reduces the risk of ischemia, among others.
参考来源
- Gempeler A, Gaviria L, Ortiz A, et al. Effect of an Albumin Infusion Treatment Protocol on Delayed Cerebral Ischemia and Relevant Outcomes in Patients with Subarachnoid Hemorrhage. Neurocrit Care. 2023. PMID: 37231237. doi:10.1007/s12028-023-01731-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。